Cytosine arabinoside (AraC) is rapidly inactivated via systemic deamination with half-lives ranging from 1 h (i.v.) to 4 h (s.c.) -and cannot be applied orally due to its hydrophilic properties. These limitations might be overcome by YNK01 -a lipophilic prodrug of AraC -that is resistant to deoxycytidine deaminase and can be applied orally. In the present study the therapeutic activity, side-effects and pharmacokinetics of YNK01 were evaluated in a phase I/II study including patients with relapsed or refractory acute myeloid leukemia ( 
Introduction
Cytarabine ocfosfate (YNK01, 1-␤-d-arabinofuranosylcytosine 5Ј-stearylphosphate) is a lipophilic derivative of cytosine arabinoside (AraC). The nucleoside analogue cytosine arabinoside is one of the most effective agents in the treatment of hematoCorrespondence: J Braess, Georg-August-University, Department of Hematology and Oncology, Robert-Koch-Strasse 40, 37075 Gö ttingen, Germany; Fax: 49 551 39 2914 Received 17 April 1998; accepted 26 June 1998 logical malignancies. Especially in the treatment of acute myelogenous leukemias AraC constitutes the basis of most currently used combination regimens. [1] [2] [3] Due to its hydrophilic properties, AraC cannot be applied via the oral route but must be given by intravenous (i.v.) or subcutaneous (s.c.) injection. Following i.v. or s.c. application AraC is rapidly deaminated by the ubiquitous cytidine deaminase to its non-cytotoxic metabolite uracil arabinoside (AraU) [4] [5] [6] resulting in short plasma half-lives of approximately 1 (i.v.) to 4 (s.c.) h only. In an attempt to overcome these limitations a series of lipophilic AraC analogues was synthesized. 7 Of these, cytarabine ocfosfate (YNK01) with a C18 chain as the lipid moiety revealed the highest antileukemic activity in vitro and in animal models and was therefore further pursued. 8 In preclinical investigations (H Takayama, 1990 ; and H Takayama and Y Esumi 1990, unpublished results) it was shown that the drug is absorbed from the intestine following oral application. It is subsequently taken up into hepatocytes and slowly metabolized to AraC by a cytochrome P450-dependent oxydative enzyme system. 9 The cytotoxic nucleoside AraC is subsequently released into the systemic circulation over a prolonged period of time. Aside from the advantage of a convenient oral application these pharmacokinetic properties also suggest a prolonged systemic exposure to AraC due to long-lasting plasma levels. To further evaluate these perspectives and their clinical relevance, a phase I/II study of cytarabine ocfosfate was initiated evaluating the side-effects and therapeutic activity but particularly the pharmacokinetics of the mother drug and its two metabolites (AraC, AraU). 10 
Patients and methods

Patients
Patients with either advanced low-grade NHL or released or refractory AML were eligible for the present study. For inclusion a WHO performance status grade 3 or better, age у18 years as well as normal liver and kidney function were required. All patients were required to be ineligible for standard second/third-line treatment as judged by the local investigator in order to qualify for the investigational drug treatment. Following information about the investigational nature of the studies all patients gave their written informed consent. Prior to its initiation the study was approved by the local ethics committee at the participating institutions. The therapeutic and investigational aspects of the study are in accordance with the Declaration of Helsinki.
Treatment schedule
Preceding the first cycle of treatment in every patient a single lead dose of the respective dose level was applied for determi-nation of baseline pharmacokinetic parameters. Seventy-two hours following the lead dose cytarabine ocfosfate was given by oral administration over 14 consecutive days. The drug was applied as capsules of 100 mg kindly provided by ASTA Medica, Frankfurt/M, Germany. In order to facilitate comparative evaluations drug doses were assessed on the basis of calculated square meter concentrations rather than on the absolute levels that were clinically administered. Starting at an initial dose level of 50 mg/m 2 /day a dose escalation was performed with initial steps of 50 mg up to 200 mg/m 2 . Subsequently, doses were escalated in steps of 150 mg/m 2 starting at 300 mg/m 2 up to 900 mg/m 2 . A minimum of three patients was included at each dose level and doses were escalated to the next level if no non-hematological toxicity WHO Ͼ2 was observed.
Response and toxicity criteria
Response in AML was assessed according to CALGB criteria (1979) . A complete remission (CR) required a bone marrow smear with less than 5% blasts and a normal peripheral blood count. A partial remission (PR) was defined as a marrow infiltration of 6-25%, less than 5% blasts in the peripheral blood, a leukocyte count of 2000-4000/l (Ͼ500/l granulocytes), hemoglobin Ͼ8 g/dl and thrombocytes 25 000-100 000/l. Patients were considered as having stable disease (SD) if PR criteria were not met and no progression of disease had occurred.
In NHL CR was defined as the disappearance of all disease manifestations. A PR was diagnosed if measured lesions had regressed by more than 50% of the initial size. The bone marrow had to be negative. Stable disease (SD) was diagnosed if criteria of PR were not met but no progression of the disease had occurred.
Toxicities were assessed according to WHO criteria.
Pharmacokinetic analysis
For pharmacokinetic analyses no distinction was made between AML and NHL. Blood samples were taken prior to and 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 48, 62 and 76 h after the lead dose and after the last dose of the regular 14 day regimen to reliably establish plasma half-lives of cytarabine ocfosfate, AraC and AraU. During the treatment cycle six further samples were taken prior to the 1st, 2nd, 3rd, 6th, 9th, 12th, 14th dose in order to estimate the pseudo steady-state levels of all three substances. In order to determine the renal excretion of all three substances urine was collected for 72 h following the lead dose and the last dose of the cycle. Blood samples were collected in heparinized vacutainers to which 250 mg of tetrahdyrouridine (THU) were added for the inhibition of cytidine deaminase. Samples were immediately centrifuged, plasma was removed and instantly frozen at −20°C until analysis. Urine specimens were similarly prepared. After measuring the total urine volume and stirring thoroughly an aliquot of 50 ml was frozen at −20°C.
Cytarabine ocfosfate concentrations in plasma and urine were determined by HPLC analysis (Ramsauer et al 1994) . In brief, sample clean-up was performed using tubes filled with C 18 material. In order to reach a low limit of quantification in the range of 5 ng/ml (variation coefficient (VC) 6.8%) and of 500 pg/ml (VC 7.3) for plasma and urine, respectively, enrichment on C18 cartridges prior to elution on to the analytical column was performed. Separation modalities involved ionpairing on a reversed-phase C 6 H 5 phenyl column with a mobile phase of 50% acetonitril and 50% 0.04 m sodium phosphate buffer for isocratic elution. An UV detector was used for signal detection at 275 nm. Recovery following sample preparation was between 52 and 64%.
An HPLC assay was developed for the detection of AraU. Plasma samples were prepared by precipitation of proteins using HClO 4 and speed-vac drying of the supernatant. The specimen was then taken up in a 10-fold higher concentration compared to the original sample in order to achieve a limit of detection of 20 ng/ml. Urine samples were prepared by adding HClO 4 to the sample followed by 60 min of heating at 90°C. Samples were then eluted over SCX anion exchange columns for final cleansing. As separation modalities a 3 C 18 reversed phase column and a 5 SA cation exchange column with a 0.1 m sodium phosphate buffer as the mobile phase were used. A limit of detection of 20 ng/ml and 500 g/ml for plasma and urine, respectively, was reached. The coefficients of variance were moderately low at 14.2% and 16.5% for plasma and urine, respectively, at the detection limit and approximately 10% at higher concentrations.
For AraC detection, a radio-immunoassay first described by Enomoto (unpublished report 1990) was used in order to reach a sufficiently low limit of detection. Conditions were modified in order to optimize sample preparation by precipitating plasma samples with a low volume of acetonitril and speed-drying the supernatant. A limit of detection of 100 pg/ml and 1 ng/ml for plasma and urine was reached, respectively. The intra-assay coefficient of variation was 18% at the detection limit.
All data were analyzed by using the TOPFIT pharmacokinetic computer program which allowed an optimized adaptation of variation coefficients between the observed and calculated data, respectively. 11 The data of all three substances were fitted to a linear one-compartment model. The plasma decay curve of cytarabine ocfosfate, AraC and AraU and the cumulative renal elimination of the latter two substances were determined independently.
Results
Clinical efficacy
Twenty-three patients with AML and 20 patients with NHL were included in the study and were evaluable for clinical response. In the 23 AML patients, two CRs, four PRs and three SDs were observed. CRs were achieved at daily doses of 300 mg/m 2 and 450 mg/m 2 in relapsed patients (prior CR Ͻ1 year). PRs were observed in four patients (relapsed and refractory) at doses of 450 mg/m 2 and 600 mg/m 2 . SD was maintained in three patients (relapsed and elderly/unfit) at doses of 150, 200 and 600 mg/m 2 . From the total of 20 NHL two patients responded with a PR and six patients experienced a SD. PRs were achieved in two patients with centrocytic lymphoma and B-CLL and were maintained for 15 and Ͼ24 months at doses between 450 mg/m 2 and 750 mg/m 2 . SD was obtained in patients with centrocytic lymphoma, B-CLL (three patients), lymphoplasmocytoid lymphoma and centroblastic-centrocytic lymphoma at daily doses of 50, 100, 300 and 450 mg/m 2 .
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Toxicities
The maximum tolerated dose (MTD) was reached at the 600 mg/m 2 dose level with two of six patients not completing the first cycle due to diarrhoea WHO grades 3 and 4, respectively. Other non-hematological toxicities did not exceed WHO grades 1 and 2. Major hematological toxicities were experienced by one AML patient who went off study after one cycle due to non-recovery from hematological toxicity within 50 days after the start of treatment. In the NHL group thrombocytopenia (WHO grades 1 and 2) was the main hematological toxicity with one out of six patients at the 450 mg/m 2 
Pharmacokinetic results
Pharmacokinetic analyses were performed in 28 patients from three centers that agreed to participate in this part of the study and that provided the required material. Inclusion/exclusion requirements for the pharmacokinetic part of the study did not differ. In two patients (both B-CLL) intraindividual dose escalation was performed with patient 3 receiving subsequently doses of 50, 150 and 300 mg/m 2 /day and patient 21 receiving cycles of 450, 600, 750, 900 and 750 mg/day. All other patients were treated on a single dose level. Pharmacokinetic evaluations were performed on all the aforementioned cycles of patients 3 and 21 and on all first cycles of the remaining 26 patients. A total of 34 cycles has therefore been analyzed for pharmacokinetic purposes. The pharmacokinetic characteristics of all three substances are given in Tables 1-3 
Cytarabine ocfosfate
On average cytarabine ocfosfate first appeared after a lag-time of 1.0 h. Maximum plasma concentrations were reached after an average of 6.5 h. Plasma levels then declined with an average t 1/2 of 10.1 h. No urinary excretion of cytarabine ocfosfate was noted over the whole dose range. During dose escalation from 50 mg/m 2 to 900 mg/m 2 /day a linear relation between the cytarabine ocfosfate dose and its AUC was observed (r = 0.78, (p Ͻ 0.0001), Figure 2) . No plateauing of the AUC during dose escalation was noted. This finding is consistent with linearity of absorption of the mother drug during dose escalation.
Considerable variability in cytarabine ocfosfate AUC at a given dose was observed: still, interindividual differences in cytarabine ocfosfate AUC were more pronounced than intraindividual differences. During intraindividual dose escalations, which could be performed in two patients, correlation coefficients of 0.97 (patient 3: 346 ng·h/ml at 50 mg/m 2 dose level, 1690 at 150 mg/m 2 , 4635 at 300 mg/m 2 ) and 0.98 (patient 21: 7460 at 450 mg/m 2 , 12 800 and 13 000 at 750 mg/m 2 , 14 100 at 900 mg/m 2 ) were found (as compared to r = 0.78 for the whole group). The values of these two patients who contributed pharmacokinetic data on several dose levels did not differ significantly from the mean values of the whole group (Tables 1-3 ) and therefore did not adversely influence the correlation of YNK01 dose and AUC (Figure 2 ). Omitting these two patients results in a moderately higher correlation (r = 0.86 (P Ͻ 0.0001)).
The average plasma concentrations and the respective standard deviations of cytarabine ocfosfate at a dose level of 600 mg/m 2 mg are demonstrated in Figure 1a . This graph clearly depicts the pseudo steady state during the 14 days cycle. No accumulation was noted. 
AraC
AraC is formed from cytarabine ocfosfate through hepatic metabolism. Maximum AraC plasma levels were reached after an average of 23.2 h. AraC then gradually decreased with an average half life of 22.6 h. AraC levels reached a pseudo steady state as depicted in Figure 1b for the 600 mg/m 2 dose group (mean and standard deviation). Renal excretion of AraC was also measured. An average of 1.7% (on a molar basis) of the total given dose of cytarabine ocfosfate was excreted as AraC via the kidneys. A renal clearance of 57.3 ml/min was derived from these data.
A linear relation was observed between the cytarabine ocfosfate dose and the AraC AUC during dose escalation (r = 0.68) (eg 227 ng·h/ml at 50 mg/m 2 dose level, 783 at 150 mg/m 2 , 2838 at 450 mg/m 2 ). The variability of the AraC AUC (Table 2) at a given dose level of cytarabine ocfosfate was more pronounced (VC = 0.57) than the respective cytarabine ocfosfate AUC (Table 1 ). This finding is consistent with additive causes of variability during the course of absorption and metabolism of cytarabine ocfosfate. As a consequence, variability of AraC plasma concentrations after YNK01 is moderately higher than during continuous i. 
AraU
The main metabolite of AraC uracil arabinoside (AraU) featured a t max of 19.2 h. Plasma levels of AraU declined with an average half-life of 22.3 h. Renal excretion of AraU occurred at an average of 14.4% of the total given dose of cytarabine ocfosfate. A renal clearance of 85.2 ml/min was calculated from these data. During dose escalation a linear relation between the cytarabine ocfosfate dose and the AraU AUC was observed (r = 0.61) (eg 1767 ng·h/ml at 50 mg/m 2 dose level, 3279 at 150 mg/m 2 , 15441 at 600 mg/m 2 ). Still, the variability of the AraU AUC at a given dose level of cytarabine ocfosfate was even more pronounced than in the case of AraC.
The sum of the AraC AUC and the AraU AUC constituted the metabolic product of cytarabine ocfosfate. A linear relationship between this sum of AraC AUC and AraU AUC and cytarabine ocfosfate AUC was observed (r = 0.72 (P Ͻ 0.0001), Figure 3 ). This finding is consistent with linearity of metabolism of cytarabine ocfosfate following absorption of the drug.
Bioavailability
Usually bioavailability of a drug following oral administration is determined by measuring its AUC after intravenous vs oral administration. In the case of cytarabine ocfosfate this approach could not be followed due to intravascular hemolysis at the injection site after i.v. administration in toxicology studies in rodents. As a substitute the 'metabolic bioavailability' was determined by measuring the renal excretion of AraC and AraU: since more than 90% of cytarabine ocfosfate that is absorbed after oral administration is metabolized to AraC and AraU which are almost completely excreted via the kidneys measurement of renal excretion allows calculation of the metabolic bioavailability. Using this concept, bioavailability of cytarabine ocfosfate amounted to an average of 15.8% (on a molar basis).
Discussion
Cytarabine ocfosfate is a recently developed lipophilic analogue of cytosine arabinoside intended for oral administration. Reports of a high antineoplastic activity in preclinical trials 8 and preliminary data suggesting favorable pharmacokinetic properties 10 as compared to the mother compound have raised interest about the clinical potential of this drug. Available clinical data consist of studies with a limited number of cases 12, 13 and case reports mostly on patients with AML or myelodysplastic syndromes. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Within the limits of a phase I/II setting clinical efficacy could also be demonstrated in this trial despite the fact that patients were heavily pretreated/refractory and/or elderly and not eligible for more intensive therapy. In the AML study two relapsed and prognostically unfavorable patients achieved a CR with further patients reaching a PR (four) or SD (three) respectively. In the NHL group no CRs were reached but two long lasting PRs were noteworthy with one patient, who had previously proved to be refractory to chlorambucile/ prednisone, radiation therapy, mitoxantrone/prednimustine and fludarabine maintaining a PR which now exceeds 2 years. 29 SD was maintained in a further six patients. Dose limiting toxicity was encountered at the seventh dose escalation level (600 mg/m 2 ) with two out of six patients going off study due to grades 3 and 4 diarrhea. Another patient suffered from grade 3 diarrhea at the 900 mg/m 2 dose level which was reached in the course of an intraindividual dose escalation. Symptoms disappeared after dose reduction to 750 mg/m 2 .
Other toxicities such as nausea/vomiting or stomatitis did not exceed WHO grades 1 and 2. Thrombocytopenia was the main hematologic toxicity with one patient at the 450 and another at the 600 mg/m 2 dose level experiencing WHO grade 4 toxicity.
Even though clinical efficacy and toxicities needed to be established for the further development of YNK01 it is necessary to stress that the prodrug itself is not active (unpublished results) but that its cytotoxicity is mediated by AraC. Instead, the novel aspects of YNK01 pharmacology are its pharmacoki-
Figure 3
Correlation of the sum of AraC and AraU AUC and YNK01 AUC.
netics which are of particular interest because its molecular structure attempted to improve on several limitations of the mother compound AraC. Hence, the stearate chain renders the molecule resistant to enzymatic deamination (=inactivation) by cytidine deaminase which otherwise causes a rapid inactivation of AraC within the systemic circulation.Furthermore, instead of being a hydrophilic nucleoside like AraC, the cytarabine ocfosfate molecule has distinct lipophilic properties due to the addition of the fatty acid chain. As a consequence, cytarabine ocfosfate was expected to be quantitatively absorbed following oral administration. In fact, the data of the present study show that cytarabine ocfosfate was absorbed with a lag-time of 1.0 h and reached maximum plasma levels after 6.5 h. The rather long lag-time and the late t max are in accordance with findings in animal studies, which demonstrated that radioactively labelled YNK01 was mainly absorbed in the distal part of the small intestine (terminal ileum). During dose escalation from 50 to 900 mg/m 2 a linear relationship was found between YNK01 dose and AUC ( Figure  2 ) demonstrating that absorption of the prodrug is not saturated in the tested dose range. This phenomenon is most likely caused by the structural properties of YNK01 that feature a hydrophilic 'head' (nucleoside) and a hydrophobic tail (stearate chain) resulting in micell formation and passive absorption. An average of 15.8% of the total dose was absorbed and metabolized to AraC and AraU which constitutes the metabolic bioavailability of YNK01. Biliary excretion of unchanged YNK01 was not tested in our patients but prior animal studies showed that only minute amounts (1-2% of the dose) were excreted unchangedly into the bile.
Similarly, no renal excretion of YNK01 was noted. This was to be expected due to the lipophilic properties of the prodrug that presumably allow complete tubular reabsorption following glomerular filtration. The half-life of 10.1 h for YNK01, therefore, mainly represents the uptake of the drug into hepatocytes and its subsequent metabolism to AraC and AraU. In contrast to AraC, deamination is of no quantitative relevance to YNK01 half-life. In vitro studies have shown that YNK01 is no substrate for cytidine deaminase (unpublished data). Due to the additive processes of intestinal passage, absorption of YKN01, uptake into hepatocytes, oxydative metabolism to AraC and final release into the circulation, maximum AraC concentrations are reached late after 23.2 h. The half-life of AraC (22.6 h) following YKN01 application is significantly longer than following i.v. or s.c. application of AraC itself (about 1 and 2-4 h, respectively). Nevertheless, the mean residence time of an individual AraC molecule is independent regardless of whether application was via oral YNK01, i.v. AraC infusion or s.c. AraC injection. Instead, the prolonged persistence of AraC plasma levels following YNK01 can be explained by the existence of a pool of AraC precursors in hepatocytes which is gradually metabolized. Flip-flop kinetics are the explanation for this unusual pharmacokinetic behaviour: for most agents it can be assumed that the drug is provided to the organism in a short period of time (eg i.v. application, rapid absorption after oral application). In such a case, t 1/2 represents the sum of all processes of elimination (eg distribution, renal or hepatic excretion, metabolism). Given the case that absorption is distinctly slower than elimination, t 1/2 represents the rate limiting process of absorption. In the case of cytarabine ocfosfate, t 1/2 does therefore not represent the elimination of AraC from the systemic circulation but the preceding events of intestinal absorption of cytarabine ocfosfate, its uptake into hepatocytes, the subsequent oxydative metabolism to AraC and the final release of the nucleoside into the systemic circulation. This phenomenon also explains the virtually identical half-lives of AraC and AraU (22.6 h and 22.3 h, respectively). Even though a further step (deamination) is needed for the production of AraU this rapid process does not significantly alter the resulting half-life of AraU.
The AUCs of YNK01 and of AraC following YNK01 administration show considerable interindividual differences with variation coefficients ranging from 0.31 to 0.67 for YNK01 and from 0.57 to 1.14 for AraC at the nine tested dose levels. The most likely cause for these variabilities is the cytochrome p450-dependent oxidative metabolism of YNK01. Several antineoplastic agents such as epidophyllotoxins, ifosfamide, tamoxifen, paclitaxel and vinca alkaloids have been shown to be metabolized (and partially activated) by this enzyme system. 30 Due to large interindividual differences in enzyme acticities -partly determined by ethnic origin, 31 partly induced by other xenobiotics -wide variations in cytotoxic drug metabolism are observed, eg with a factor of 4.4 between high and low metabolizers of vinblastin 32 and of 8.9 for docetaxel. 33 Different rates of cytochrome-dependent metabolism may contribute to wide variations in drug plasma levels as exemplified by the anthrachinone mitoxantrone, also a substrate of cytochrome p450, 34 which exhibits a factor of 13 between the lowest and highest AUC following body-surface adjusted i.v. drug application. 35 Mitoxantrone, therefore, is an example of a high variability in plasma levels following i.v. administration which even exceeds the variations observed in other, orally applied, drugs such as YNK01.
Due to the long t 1/2 of AraC after oral cytarabine ocfosfate application long-lasting plasma levels of AraC are maintained mimicking a continuous i.v. infusion. When daily doses between 100 and 200 mg/m 2 of cytarabine ocfosfate were applied the resulting AraC plasma concentrations were equivalent to those achieved during low-dose (20 mg/m 2 s.c.) AraC therapy. In the 450 mg/m 2 to 600 mg/m 2 dose range of cytarabine ocfosfate AraC plasma concentrations were in the range or even exceeded those plasma concentrations achieved during continuous infusion of standard-dose AraC (100 mg/m 2 ) such as in the TAD-9 regimen. During i.v. administration of conventional AraC moderate variations in the AUC are observed with vc ranging from 0.40 (standard-dose AraC) to 0.46 (intermediate-dose AraC). In comparison, variability following oral YNK01 was only slightly higher with a vc of 0.57, most likely reflecting the additional causes of variability such as resorption and hepatic metabolism.
In conclusion, cytarabine ocfosfate represents an interesting prodrug of AraC which has been demonstrated to have clinical efficacy in poor-risk patients with AML and NHL. Sideeffects were manageable and mainly consisted of diarrhea and (AraC typical) hematotoxicity. The drug possesses attractive pharmacokinetic features comprising oral applicability and long-lasting plasma levels of AraC. Its unique pharmacokinetic properties lead to a prolonged systemic exposure of AraC mimicking a continuous i.v. infusion. This prolonged exposure allows maximization of the probability of malignant cells passing through the vulnerable phase of the cell cycle and might therefore contribute to overcoming drug resistance. Plasma levels such as in low-dose or standard-dose AraC therapy can be maintained during the whole treatment cycle. Phase II studies are now needed to establish the clinical efficacy of this drug and to define its most appropriate indications.
